In his weekly clinical update, Dr. Griffin discusses clearance of longstanding, immune-deficiency-associated, vaccine-derived poliovirus infection following remdesivir therapy for chronic SARS-CoV-2 infection, SARS-CoV-2 exposure in New York City rats, clinical characteristics and outcomes of children with SARS-CoV-2 infection during the Delta and Omicron variant-dominant periods in Korea, exhaled breath aerosol shedding of SARS-CoV-2 variants, outpatient treatment of COVID-19 and the development of long COVID over 10 months, Nirmatrelvir and the risk of post-acute sequelae of COVID-19, assessment of the risk of venous thromboembolism in nonhospitalized patients with COVID-19, and the optimal duration of systemic corticosteroids in COVID-19 treatment.

Click arrow to play Download TWiV 992 (19 MB .mp3, 32 min)

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Clearance of vaccine-derived poliovirus following remdesivir therapy for SARS-CoV-2 infection (Frontiers)
• SARS-CoV-2 exposure in Norway rats from New York City (mBio)
• Clinical characteristics and outcomes of children with SARS-CoV-2 Infection in Korea (JKMS)
• Exhaled breath aerosol shedding of SARS-CoV-2 variants (CID)
• Outpatient treatment of COVID-19 and the development of Long COVID (The Lancet)
• Nirmatrelvir and the risk of post-acute sequelae of COVID-19 (medRxiv)
• Risk of venous thromboembolism in nonhospitalized patients with COVID-19 (JAMA)
• Optimal duration of systemic corticosteroids in COVID-19 treatment (OFID)
• Contribute to our ASTMH fundraiser at PWB
• Dr. Griffin's treatment guide (pdf)
• Letters read on TWiV 992
• Don't crush Paxlovid (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]